A Splendid New Beginning at the End of a 40-Year Quest: The First KRASG12D Inhibitor in Pancreatic Cancer

Cancer Discov. 2023 Feb 6;13(2):260-262. doi: 10.1158/2159-8290.CD-22-1304.

Abstract

The first KRASG12D inhibitor, MRTX113, leads to regression in multiple mouse models of PDAC as a monotherapy. MRTX113 blocks cancer cell proliferation, induces cancer cell death, and promotes immune infiltration and activation. See related article by Kemp et al., p. 298 (6).

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Animals
  • Carcinoma, Pancreatic Ductal* / drug therapy
  • Carcinoma, Pancreatic Ductal* / genetics
  • Carcinoma, Pancreatic Ductal* / metabolism
  • Cell Proliferation
  • Mice
  • Mice, Transgenic
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / genetics
  • Pancreatic Neoplasms* / metabolism